CCRN Stock News & Analysis | Latest Updates

Cross Country Healthcare Announces Second Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its second quarter ended June 30, 2025. Selected Financial Information: Variance Variance Q2 2025 vs Q2 2025 vs Dollars are in thousands, except per share amounts Q2 2025 Q2 2024 Q1 2025 Revenue $ 274,072 (19 )% (7 )% Gross profit margin* 20.4 % (40 )bps 40 bps Net loss attributable to common stockholders $ (6,659 ) (59 )% (1,259 )% Diluted

August 6, 2025Earnings

UBS Maintains Neutral on Cross Country Healthcare, Lowers Price Target to $16.5

CCRN

May 13, 2025

Cross Country Healthcare Q1 Adj. EPS $0.06, Inline, Sales $293.41M Miss $305.48M Estimate

CCRN

May 7, 2025

Watching Shares Of Cross Country Healthcare; Traders Circulate Comments From M&A Blog

CCRN

March 6, 2025

Cross Country Healthcare Q4 2024 Adj. EPS $0.04 Misses $0.12 Estimate, Sales $309.940 Miss $306.100M Estimate

CCRN

March 5, 2025

Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

CCRN

February 28, 2025

Cross Country Healthcare Sees Q4 Adj. EPS $0.10-$0.14, Revenue $300M-$310M

CCRN

November 6, 2024

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

CCRN

November 6, 2024

A Peek at Cross Country Healthcare's Future Earnings

CCRN

November 5, 2024

Cross Country Healthcare 8K Filing Revising Its Guidance For Q3 With Respect To Revenue, Adj. EBITDA, And Adj. EPS Guidance; Sees Q3 2022 Revenue $615M-$625M; Sees Q3 2022 Adj. EPS $0.90-$1.00; Q3 SHR View $0.91, Rev View $610.5M

CCRN

September 14, 2022

Cross Country Healthcare Sees Q2 Adj. EPS $1.30-$1.40 vs $0.90 Estimate, Sales $735M-$745M vs $608M Est.

CCRN

May 4, 2022

Cross Country Healthcare Q1 Adj. EPS $1.70 Beats $1.31 Estimate, Sales $788.73M Beat $745.64M Estimate

CCRN

May 4, 2022

CCRN News

Cross Country Healthcare Announces Second Quarter 2025 Financial Results

UBS Maintains Neutral on Cross Country Healthcare, Lowers Price Target to $16.5

Cross Country Healthcare Q1 Adj. EPS $0.06, Inline, Sales $293.41M Miss $305.48M Estimate

Watching Shares Of Cross Country Healthcare; Traders Circulate Comments From M&A Blog

Cross Country Healthcare Q4 2024 Adj. EPS $0.04 Misses $0.12 Estimate, Sales $309.940 Miss $306.100M Estimate

Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

Cross Country Healthcare Sees Q4 Adj. EPS $0.10-$0.14, Revenue $300M-$310M

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

A Peek at Cross Country Healthcare's Future Earnings

Cross Country Healthcare 8K Filing Revising Its Guidance For Q3 With Respect To Revenue, Adj. EBITDA, And Adj. EPS Guidance; Sees Q3 2022 Revenue $615M-$625M; Sees Q3 2022 Adj. EPS $0.90-$1.00; Q3 SHR View $0.91, Rev View $610.5M

Cross Country Healthcare Sees Q2 Adj. EPS $1.30-$1.40 vs $0.90 Estimate, Sales $735M-$745M vs $608M Est.

Cross Country Healthcare Q1 Adj. EPS $1.70 Beats $1.31 Estimate, Sales $788.73M Beat $745.64M Estimate